Full-Time

Marketing Associate

Undergraduate Placement

Confirmed live in the last 24 hours

Illumina

Illumina

5,001-10,000 employees

Supports genomics startups through funding and resources

Venture Capital
Biotechnology

Entry

Company Historically Provides H1B Sponsorship

Cambridge, UK

The role is a 12-month placement starting in July 2025, finishing July 2026, and is based at the offices in Granta Park, Cambridge.

Category
General Marketing
Growth Marketing
Growth & Marketing
Required Skills
Sales
Lead Generation
Marketing
Data Analysis
Excel/Numbers/Sheets

You match the following Illumina's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Keen interest in marketing and/or sales
  • Currently studying within a BSc program
  • Experience and knowledge in the life science field (advantage)
  • Advanced Excel skills (VLOOKUP, pivot tables)
  • Comfortable with CRM tools (Salesforce.com) and other business software solutions
  • Outstanding listening, verbal, and written communication skills
  • Demonstrable ability to analyse data and communicate key messages clearly
  • Strong interpersonal skills
  • Efficient time management skills
Responsibilities
  • Responsible for the reporting & qualification of marketing generated leads
  • Support prospecting efforts to find new business
  • Makes outbound contact to existing and prospective customers to identify sales opportunities, promote relevant marketing/sales promotional programs and initiate the sales process
  • Responsible for entering and maintaining lead data into our customer relationship management database
  • Work closely with Marketing Programs and Lead Generation Specialist and build effective customer journey to fill the funnel with high quality leads
  • Take ownership on key initiatives that support funnel management in the region and across regions
Desired Qualifications
  • Experience and knowledge in the life science field (advantage)

Illumina focuses on building a supportive environment for startups in the genomics field. Their main initiative, Illumina Accelerator, helps entrepreneurs create and grow genomics companies by providing funding and resources. The accelerator is located in both the San Francisco Bay Area and Cambridge, UK, and has successfully invested in 68 genomics startups, which have collectively raised over $1 billion in venture capital. What sets Illumina apart from other accelerators is its strong partnership with leading venture capital investors and its specific focus on the genomics industry. The goal of Illumina is to foster innovation and growth in genomics, ultimately advancing the field and its applications.

Company Size

5,001-10,000

Company Stage

IPO

Total Funding

$27.2M

Headquarters

San Diego, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Illumina's partnership with Broad Labs aims to create a 5 billion cell atlas.
  • The Truveta Genome Project collaboration enhances Illumina's genomic data integration.
  • Illumina's spatial technology expands applications in cellular behavior studies.

What critics are saying

  • Increased competition from Truveta challenges Illumina's genomic data market position.
  • NVIDIA's partnerships with other healthcare organizations may outpace Illumina's AI offerings.
  • Regulatory changes in AI could impact Illumina's AI-driven initiatives.

What makes Illumina unique

  • Illumina's spatial transcriptomics technology maps complex tissues at an unprecedented scale.
  • The MiSeq i100 series offers compact, powerful sequencing with numerous patents.
  • Illumina's collaboration with NVIDIA enhances AI-driven genomic analysis capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
PR Newswire
Feb 21st, 2025
Illumina And Broad Clinical Labs Usher In New Era Of Drug Discovery With Collaboration To Rapidly Scale Single-Cell Solutions

Longstanding partners bring together end-to-end workflows and leading CRISPRPerturb-seq technologies setting a standard for single-cell studies and enabling a 5billion single-cell atlas ecosystem within three yearsSAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows. Together, the longstanding partners will set the standard for scalable single-cell research and accelerate the development of a 5 billion cell atlas within the next three years

PR Newswire
Feb 19th, 2025
Illumina Unveils First-Of-Its-Kind Spatial Transcriptomics Technology

Broad Institute to collaborate on flagship project tapping Illumina's new spatial technologyAt AGBT, customers will present data demonstrating unparalleled scale and sensitivity in research spanning pulmonary fibrosis, prostate cancer, and 3D reconstructions of mouse brainsCompany expands software portfolio to decode multimodal data with Illumina Connected MultiomicsSAN DIEGO, Feb. 19, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity. These capabilities are expected to drive expansion of spatial research and unlock applications and experiments that were previously not possible.Illumina has announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. Details and early access customer data will be presented next week during Illumina’s Gold Sponsor Workshop at the Advances in Genome Biology and Technology General Meeting in Florida.Details and early access customer data will be presented next week during Illumina's Gold Sponsor Workshop at the Advances in Genome Biology and Technology (AGBT) General Meeting in Florida."Spatial transcriptomics opens entirely new pathways to gain crucial insight into the cellular function of organisms," said Steve Barnard, PhD, chief technology officer of Illumina

PR Newswire
Feb 18th, 2025
Illumina To Webcast Upcoming Investor Session At The Advances In Genome Biology And Technology (Agbt) Conference

SAN DIEGO, Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session at the AGBT conference.The investor fireside chat will begin at 8:00am Pacific Time (11:00am Eastern Time) on Tuesday, February 25, 2025 and will feature Jacob Thaysen (Chief Executive Officer), Ankur Dhingra (Chief Financial Officer), and Steve Barnard (Chief Technology Officer).Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link – (https://illumina-agbt-investor-session-feb-2025.open-exchange.net/) To ensure timely connection, please join at least ten minutes before the scheduled start of the session.A replay will be posted on Illumina's website after the event and will be available for at least 30 days following.About IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter) , Facebook , LinkedIn , Instagram , TikTok , and YouTube .Investors:Salli Schwartz+1.858.291.6421[email protected]Media:Bonny Fowler+1.740.641.5579[email protected]SOURCE Illumina, Inc

Illumina
Jan 21st, 2025
Inside the new Illumina MiSeq i100 Series: The making of the software

Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families.

PYMNTS
Jan 17th, 2025
This Week In Ai: Biden Signs Executive Orders; Nvidia Targets Healthcare

This week in artificial intelligence, President Joe Biden issued executive orders related to AI leadership and safety while Nvidia unveiled partnerships with healthcare organizations to accelerate drug discovery. OpenAI, Amazon and Elon Musk were also in the news. Biden’s Executive Orders Focus on Governance, Safety. President Joe Biden issued executive orders related to maintaining leadership of AI in the United States and policies to protect against potential AI harms